Key result
Addition of IGF-I/IGF-binding protein-3 to a GH receptor antagonist significantly improved the insulin sensitivity index compared to the GH antagonist alone (4.34 vs 2.7 x 10(-4)/min. micro U/ml).
Why the study?
Does the combination of IGF-I/IGF-binding protein-3 improve insulin sensitivity in patients with active acromegaly treated with a GH receptor antagonist?
Does the combination of IGF-I/IGF-binding protein-3 improve insulin sensitivity in patients with active acromegaly treated with a GH receptor antagonist?
Absolute Event Rate: 4.34% vs 2.7%
IGF-I has insulin-sensitizing actions that are independent of its ability to suppress GH secretion in patients with acromegaly.
No takes yet. Share an insight, caveat, or question.
May suggest adjunctive benefit in acromegaly on GH antagonist; hypothesis-generating and leaves open need for randomized confirmation.
O’Connell et al. (2002) studied active acromegaly and insulin resistance (n=5). IGF-I/IGF-binding protein-3 vs. GH receptor antagonist alone was evaluated on insulin sensitivity index. Addition of IGF-I/IGF-binding protein-3 to a GH receptor antagonist significantly improved the insulin sensitivity index compared to the GH antagonist alone (4.34 vs 2.7 x 10(-4)/min. micro U/ml).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: